Semaglutide Benefits Heart Failure Patients Regardless of Frailty Status | Research

The takeaway

Semaglutide improved heart failure symptoms, physical limitations, and reduced body weight in obesity-related HFpEF patients regardless of their frailty status, and also improved frailty itself.

Frailty improved
Semaglutide not only worked across frailty levels but improved frailty scores themselves in HFpEF patients

What the researchers found

Semaglutide's efficacy in obesity-related HFpEF was consistent across frailty subgroups, and semaglutide treatment itself improved frailty status — a novel and clinically significant finding.

Why it matters

Frailty is extremely common in HFpEF and is associated with worse outcomes. Clinicians often hesitate to use weight loss drugs in frail patients, fearing they might worsen frailty. This study shows semaglutide is not only safe but actually beneficial across the frailty spectrum.

The numbers in context

Of 1,145 participants, 60.4% were most frail, 30.0% more frail, 9.6% nonfrail. Weight loss was similar across groups (P-interaction = 0.38). Treatment lasted 52 weeks with semaglutide 2.4 mg once weekly.

How the study worked

Secondary analysis of the STEP-HFpEF randomized controlled trial program. Participants were stratified by baseline frailty status, and semaglutide's effects on HF symptoms, physical limitations, body weight, and frailty scores were assessed across subgroups.

Who was studied

Adults with obesity-related HFpEF from the STEP-HFpEF program

What this study cannot tell us

Secondary analysis of existing trial data; frailty assessment tools may not capture all dimensions of frailty; trial participants may not represent the most frail patients seen in clinical practice; mechanisms behind frailty improvement not elucidated.

How to read the evidence

Secondary analysis of a major randomized controlled trial program (STEP-HFpEF). High-quality evidence, though secondary analyses are hypothesis-generating rather than definitive.

When this study was published

Published in 2025, based on the landmark STEP-HFpEF trial program data.

The bigger picture

This is an important piece of the growing evidence that GLP-1 drugs may fundamentally alter the trajectory of obesity-related heart failure. The finding that semaglutide improves frailty — not just heart failure markers — suggests broader anti-aging and functional benefits.

Questions still open

What specific mechanisms drive semaglutide's improvement in frailty scores — is it purely weight/inflammation reduction or something more?
Should semaglutide be recommended specifically for frail HFpEF patients as a frailty intervention?
Do the frailty benefits persist long-term after the trial period?

Common questions

What is frailty and why does it matter in heart failure?

Frailty is a state of increased vulnerability characterized by weakness, fatigue, slow walking, and weight loss. In heart failure, frailty dramatically increases the risk of hospitalization and death. Doctors often worry that weight loss drugs could worsen frailty, making this study's findings especially important.

What is HFpEF and why is it hard to treat?

HFpEF (heart failure with preserved ejection fraction) is a type of heart failure where the heart squeezes normally but can't relax and fill properly. Unlike other forms of heart failure, very few treatments have been proven to work. Semaglutide is emerging as one of the first effective options, especially in patients whose HFpEF is driven by obesity.

Read the original research

Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.

JACC. Heart failure, 13(10), 102610

View on PubMed ↗Publisher’s paper ↗

Citation

Pandey, Ambarish; Kitzman, Dalane W; Chinnakondepalli, Khaja M; Patel, Shachi; Borlaug, Barry A; Butler, Javed; Davies, Melanie J; Shah, Sanjiv J; Verma, Subodh; Rönnbäck, Cecilia; Domdey, Anne; Liisberg, Karoline; Schou, Morten; Perna, Eduardo; Ahmed, Fozia Z; Fu, Michael; Petrie, Mark C; Kosiborod, Mikhail N. (2025). Frailty and Effects of Semaglutide in Obesity-Related HFpEF: Findings From the STEP-HFpEF Program.. JACC. Heart failure, 13(10), 102610. https://doi.org/10.1016/j.jchf.2025.102610